Gwangju Institute of Science & Technology, National Cancer Center of Korea and Seoul National University have jointly divulged new PreS1 (hepatitis B virus, HBV) derivatives for the treatment of HBV infection.
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense oligonucleotide candidate as a functional cure for chronic hepatitis B.
Researchers from Suzhou Siran Biotech Co. Ltd. presented the discovery and preclinical characterization of SA-1211, an N-acetylgalactosamine (GalNAc)-conjugated siRNA dimer targeting both hepatitis B virus (HBV) and PD-L1 gene expression, being developed as a potential new therapeutic candidate for the treatment of chronic hepatitis B (CHB).
Researchers from presented preclinical data for AVX-70371, a novel therapeutic vaccine being developed for the treatment of chronic hepatitis B virus (HBV) infection.
Functionally active hepatitis B virus (HBV) DNA is open and accessible, while the action of an epigenetic editor turns it into functionally inactive DNA, which is closed and inaccessible. Chroma Medicine Inc. has presented data regarding their epigenetic editor CRMA-1001, which is delivered by lipid nanoparticles.
Gigagen Inc., a subsidiary of Grifols SA, has received clearance from the FDA of its IND application to conduct a phase I trial of GIGA-2339 for the treatment of hepatitis B virus (HBV) infections.
SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).
SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).
Previous studies have found that the effectiveness of vaccines can be increased with the knockdown of HBsAg using a small interfering RNA (siRNA). The efficacy of a bivalent mRNA vaccine in combination with the siRNA AD-66810, which targets the X gene expression in the hepatitis B virus (HBV) genome, was tested in a murine model of AAV/HBV by scientists from Clearb Therapeutics Inc.
